The firm noted that the premarket approval means that the three major viral load assays that most laboratories run for patients are now available on a single system.
While the virus they found appears old, the researchers found it to be closely related to modern ones, indicating that it has infected people for centuries.
Medcis Pathlabs and its associates and attendees will buy Co-Diagnostics' tests for hepatitis B, hepatitis C, HIV, and human papillomavirus.
The test adds to the firm's current portfolio of 30 infectious disease and oncology tests that use its Sentosa PCR and NGS workflow.
Following a beta evaluation of the system, a virology lab in Sheffield, UK, ran a workflow assessment and found improvements with the system.
The tests are the first assays approved by the FDA to run on the firm's Cobas 6800 and Cobas 8800 systems.
The DxN Veris was recently launched as a CE-marked product with a menu of viral load tests, and will launch in a few years in the US with STD and HAI assays.
The new company will be focused entirely on hepatitis B, although officials previously said that Tekmira's other non-HBV RNAi programs would continue to advance.
The new assay expands a portfolio of viral load monitoring tests for the Cobas 6800 and 8800 systems.
The company also recently paid $7 million for an exclusive option on an undisclosed RNAi technology and related intellectual property.
A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.
Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.
In Science this week: CRISPR-based approach for recording cellular events, and more.
A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.